| Background and objective: Angiogenesis plays a critical role in the growth and metastasis of tumors. Vascular endothelial growth factor is the most potent and specific angiogenic factor. VEGF has 5 subtypes, which are 121, 165, 189, 206, 145-amino acid proteins based on alternative splicing. VEGF165 is the most effective growth factor for endothelial cells among them. A recombinant humanized monoclonal antibody to VEGF has been recently developed and studied in clinical trials in different tumors through inhibiting tumor angiogenesis. As specific active immunotherapy, tumor vaccine can induce specific active immune response and reinforce anti-tumor effect, which has been confirmed in vivo. Many vaccines have applied into clinical research. Phage display technique is based on the linking mechanism of gene and protein. Recombinant phage vaccine, belonging to vector-viral vaccine, has advantages of both DNA vaccine and protein vaccine, which can make researchers not only modulate the stereo-configuration of protein by modifying DNA on gene level, but detect the protein displayed. It combines sequence analysis with protein function study easily and effectively. Phage T7 is a desirable vector because it is not only a small type phage with the features of convenient operation, easy culture, rapid growth and stable system, but also antigen can be displayed on its capsid as fusion protein. T7select10-3b kit was applied to display exogenous peptide in our study. Exogenous peptide which is smaller than 1200 aa can be fused to the 10B capsid protein (5-15 copies /phage). Human VEGF and mouse VEGF are 89% identical at amino acid level. This study was designed to construct...
|
PDF Full Text Request